| DIRECT COMPETITOR COMPARISON | |
| BSTC | Pvt1 | PFE | PPTI.PK | Industry | | Market Cap: | 190.04M | N/A | 149.21B | 1.58M | 97.82M | | Employees: | 5 | N/A | 81,800 | 2 | 65 | | Qtrly Rev Growth (yoy): | 139.50% | N/A | -2.90% | -99.40% | 19.70% | | Revenue (ttm): | 9.63M | N/A | 45.82B | 3.65K | 14.01M | | Gross Margin (ttm): | 96.03% | N/A | 86.61% | N/A | 65.68% | | EBITDA (ttm): | 4.32M | N/A | 21.31B | -1.26M | -12.30M | | Oper Margins (ttm): | 44.25% | N/A | 37.42% | -34,943.40% | -137.11% | | Net Income (ttm): | 3.81M | N/A | 8.09B | -1.32M | N/A | | EPS (ttm): | 0.543 | N/A | 1.204 | -0.012 | -0.31 | | P/E (ttm): | 55.56 | N/A | 15.36 | N/A | 16.76 | | PEG (5 yr expected): | N/A | N/A | 6 | N/A | 1.28 | | P/S (ttm): | 19.11 | N/A | 3.28 | 356.39 | 9.45 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.85 | 0.53% | 57.54B | 12.40 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 48.18 | 1.69% | 13.93B | 16.12 | | Genzyme Corp. | GENZ | 49.98 | -0.58% | 13.26B | 28.49 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.59 | 0.71% | 41.93B | 18.02 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.64 | 0.78% | 9.03B | 1033.47 | | Teva Pharmaceutical Industries Limited | TEVA | 54.01 | 0.82% | 47.58B | 49.41 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.90 | 1.64% | 4.02B | 19.54 | | King Pharmaceuticals Inc. | KG | 11.72 | 0.43% | 2.91B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 17.99 | -1.15% | 5.50B | 110.37 | | Pfizer Inc. | PFE | 18.49 | -0.80% | 149.21B | 15.36 | | Johnson & Johnson | JNJ | 64.36 | 0.31% | 177.58B | 14.06 | | GlaxoSmithKline plc | GSK | 42.75 | 0.73% | 108.37B | 13.44 | | Sanofi-Aventis | SNY | 39.38 | -0.35% | 102.83B | N/A | | Novartis AG | NVS | 55.55 | -0.41% | 126.17B | 16.63 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 41.42 | -1.03% | N/A | N/A | | AstraZeneca plc | AZN | 46.30 | 1.49% | 67.13B | 9.30 | | Abbott Laboratories | ABT | 53.78 | -0.85% | 83.18B | 14.57 | | Bristol-Myers Squibb Co. | BMY | 25.14 | -0.08% | 49.80B | 13.01 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | PFE | | Antipsychotics, Diabetes & Kids
Fri 5:26pm -
at The Wall Street Journal Online | | • | PFE | | After Rising 500%, What Did You Expect?
Fri 2:19pm -
at Motley Fool | | • | PFE | | Ratiopharm gets higher offers, to winnow bidders
Fri 1:14pm -
at Reuters | | • | PFE | | [video] Health Care Stock Picks
Fri 1:07pm -
at Forbes.com | | • | PFE | | FDA Panel Recommends Antipsychotic-Drug Review of Kids' Weight Gain
Fri 12:33pm -
at The Wall Street Journal Online | | • | PFE | | UPDATE - FDA staff urge more antipsychotic review in kids
Fri 12:19pm -
at Reuters | | • | PPTI.PK | | PROTEIN POLYMER TECHNOLOGIES INC Financials
Thu, Nov 26 -
EDGAR Online Financials | | • | PPTI.PK | | PROTEIN POLYMER TECHNOLOGIES INC Files SEC form 10-Q, Quarterly Report
Mon, Nov 23 -
EDGAR Online | | • | PPTI.PK | | PROTEIN POLYMER TECHNOLOGIES INC Files SEC form 10-Q/A, Quarterly Report
Thu, Aug 20 -
EDGAR Online | | • | PPTI.PK | | PROTEIN POLYMER TECHNOLOGIES INC Files SEC form 10-K, Annual Report
Fri, Jul 24 -
EDGAR Online | | • | PPTI.PK | | PROTEIN POLYMER TECHNOLOGIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Tue, Jul 7 -
EDGAR Online | | | All Headlines for these symbols... |
|
|
|
0.22% Nasdaq 
Competitors
